A Cognitive Behavioral Therapy Group Intervention to Increase HIV Testing and PrEP Use Among Latinx Sexual Minority Men

This study consists of a randomized controlled trial (RCT) of a multi-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP use among Latinx sexual minority men (SMM).

Study Overview

• Status: Recruiting
• Conditions: HIV
• Intervention / Treatment: Behavioral: CBT Coping Intervention

Detailed Description

This study consists of a randomized controlled trial (RCT) of a multi-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP use among Latinx sexual minority men (SMM). We will test intervention effects on regular HIV testing and use of prevention strategies. The intervention was developed in partnership with community stakeholders at Bienestar Human Services, Inc., a Latinx-focused organization in Los Angeles County (LAC), CA. The intervention is flexible for use in community-based organizations, such as in ongoing support groups.

The Specific Aims are:

Aim 1. To conduct a randomized controlled trial of a culturally congruent cognitive behavior therapy group intervention for immigrant Latinx sexual minority men, to test intervention effects on regular HIV testing and PrEP uptake.

Aim 2. To examine mechanisms of intervention effects on regular HIV testing and PrEP uptake, including more effective coping (e.g., reduced internalized stigma).

Aim 3. To conduct a cost-effectiveness analysis of the intervention.

• Study Type: Interventional
• Enrollment (Estimated): 300
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Laura Bogart, PhD; Phone Number: 7281 (310) 393-0411; Email: lbogart@rand.org
• Study Contact Backup: Name: Terry Marsh, MPH; Phone Number: 6846 (310) 393-0411; Email: tmarsh@rand.org

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90022
      • Recruiting
      • Bienestar Human Services, Inc
      • Contact: Ronald Brooks, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• at least 18 years-old
• biologically male at birth
• identify as male
• identify as Latino
• is an immigrant
• report having sex with men in the past 12 months
• report HIV-negative or unknown serostatus
• anticipate being available for the next 12 months to attend study visits
• able to interact and communicate in spoken Spanish or English.

Exclusion Criteria:

• HIV-positive
• cisgender women
• transgender women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CBT Coping Intervention; The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).	Behavioral: CBT Coping Intervention; A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
No Intervention: Control; Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants who are HIV tested at least annually	Participants report being tested for HIV at least once in the past 12 months	from baseline to 12-months
Proportion of participants who have taken PrEP in the past 12 months	Participants report taking PrEP at any follow-up time-point	from baseline to 12-months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in average level of adaptive coping, measured by the Brief COPE	Average adaptive coping rating on the Brief COPE scale (higher=better coping; range=1-4)	from baseline to 12-months

Collaborators and Investigators

• Sponsor: RAND
• Collaborators: Bienestar Human Services, Inc.
• Investigators: Principal Investigator: Laura Bogart, PhD, RAND

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2020
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: January 7, 2020
• First Submitted That Met QC Criteria: January 8, 2020
• First Posted (Actual): January 13, 2020

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: men who have sex with men; Latino/Hispanic/Latinx
• Other Study ID Numbers: R01MH121256 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No